10x Genomics (TXG) P/B ratio
10x Genomics (TXG) trades at 8.8× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 2.6×. That is 4.9% higher than the 2.4× of fiscal 2024. Figures as of 18 Nov 2026, 09:31 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/B ratio today
- 8.8×
- P/B ratio, fiscal 2025
- 2.6×
- Change on fiscal 2024
- +4.9%
- Highest on record
- 20.1×fiscal 2021
- Lowest on record
- 2.4×fiscal 2024
- Fiscal years on record
- 72019–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
10x Genomics P/B ratio, in more detail
Today's figure is 245.2% above the fiscal 2025 year-end.
Across the 7 fiscal year-ends on record (2019–2025), the highest was 20.1× in fiscal 2021 and the lowest 2.4× in fiscal 2024. Today's P/B ratio is higher than at 57% of the 7 fiscal year-ends on record; their median is 7.1×.
P/B ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
10x Genomics P/B ratio, year by year
| Fiscal year | P/B ratio | Change | Year ended | Share price at year-end | Book value per share |
|---|---|---|---|---|---|
| Today | 8.8× | — | $56.30 | — | |
| 2025 | 2.6× | 4.9% up | $16.31 | $6.38 | |
| 2024 | 2.4× | 72.5% down | $14.36 | $5.90 | |
| 2023 | 8.8× | 71.8% up | $55.96 | $6.32 | |
| 2022 | 5.1× | 74.4% down | $36.44 | $7.08 | |
| 2021 | 20.1× | 3.7% up | $148.96 | $7.41 | |
| 2020 | 19.4× | 173.1% up | $141.60 | $7.31 | |
| 2019 | 7.1× | — | $76.25 | $10.75 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
How to read it
It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.
P/B ratio at health care companies of similar size
| Company | P/B ratio |
|---|---|
| Twist Bioscience TWST | 8.4× |
| Protagonist Therapeutics PTGX | 13.2× |
| Krystal Biotech KRYS | 7.3× |
| 10x Genomics TXG | 9.3× |
| HealthEquity HQY | 4.0× |
| Corcept Therapeutics CORT | 11.8× |
Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.
10x Genomics, figure by figure
- 10x Genomics market cap
- 10x Genomics revenue
- 10x Genomics earnings
- 10x Genomics earnings per share (EPS)
- 10x Genomics P/E ratio
- 10x Genomics P/S ratio
- 10x Genomics free cash flow
- 10x Genomics operating margin
- 10x Genomics dividend
- 10x Genomics shares outstanding
- 10x Genomics total debt
- 10x Genomics cash on hand
- 10x Genomics total assets
- 10x Genomics return on equity (ROE)
- 10x Genomics return on invested capital (ROIC)
10x Genomics (TXG) overview: price, valuation and scorecardAll health care companies by market value
10x Genomics P/B ratio: questions and answers
What is 10x Genomics's P/B ratio?
10x Genomics (TXG) trades at 8.8× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 2.6×. That is 4.9% higher than the 2.4× of fiscal 2024.
Is 10x Genomics's P/B ratio high or low compared with its own history?
Today's P/B ratio is higher than at 57% of the 7 fiscal year-ends on record; their median is 7.1×.
What are the highest and lowest P/B ratio figures on record for 10x Genomics?
Across the 7 fiscal year-ends on record (2019–2025), the highest was 20.1× in fiscal 2021 and the lowest 2.4× in fiscal 2024.
How is 10x Genomics's P/B ratio calculated?
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For 10x Genomics it is on record here for 7 fiscal years, 2019 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/B ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “10x Genomics (TXG) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/TXG/pb-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.